Recombinant human bone morphogenic protein-2 in fracture care.
Recombinant human bone morphogenic protein-2 (rhBMP-2) is an osteoinductive protein that is now available for the acute treatment of open tibial fracture. Data from preclinical and clinical trials support its role in fracture care. This article summarizes data from two randomized controlled clinical trials investigating the safety and efficacy of rhBMP-2 in patients with open tibial shaft fractures and tibial fractures with bone defects. Also included is a summary of an economic analysis that examined the cost impact of rhBMP-2 from a hospital and payor perspective.
Baylor University Medical Center at Dallas, Dallas, TX 75246-1800, USA. AlanJ@BaylorHealth.edu
Alan L
AL
Jones
D019485:Bone Morphogenetic Proteins / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D017102:Fracture Healing / Q000187:drug effects*; D005597:Fractures, Open / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D013978:Tibial Fractures / Q000188:drug therapy* / Q000601:surgery
D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins